Asparagine Market by Type, Application - Global Forecast 2024-2030

List of Tables

[183 Pages Report] The Asparagine Market size was estimated at USD 11.81 billion in 2023 and expected to reach USD 12.40 billion in 2024, at a CAGR 5.29% to reach USD 16.96 billion by 2030.

Asparagine, an amino acid, plays a fundamental role in the biosynthesis of proteins. It is an essential component required for the development and functioning of the brain and is a precursor to neurotransmitters. The asparagine market spans various industries, including biotechnology, food and beverage, pharmaceuticals, and animal feed, showcasing its broad spectrum of utilizations. Analyzing the market requires insights into its applications, end-uses, market scope, growth opportunity factors, limitations, and potential areas of innovation. Rising health consciousness for dietary supplements and increased investment in R&D in the pharmaceutical industry are driving the market growth. Ongoing innovations in the food and beverage industry are also propelling the market. Fluctuations in the prices of raw materials and stringent regulations and standards regarding the use of asparagine are restricting market growth. The development of novel pharmaceutical formulations containing asparagine and the rise in precision medicine and targeted therapies are expected to create opportunities in the market.

KEY MARKET STATISTICS
Base Year [2023]	USD 11.81 billion
Estimated Year [2024]	USD 12.40 billion
Forecast Year [2030]	USD 16.96 billion
CAGR (%)	5.29%

Regional Insights

The Asparagine market in the Americas is characterized by advanced biotechnology sectors, particularly in North America. The United States produces and consumes Asparagine, predominantly for the pharmaceuticals and food industries. South America's market is emerging, with Brazil showing increasing demand for Asparagine in food additive applications and research. Stringent regulations on North American food additives and clinical nutrition bolster the demand for high-purity Asparagine. The Asia-Pacific, led by China, Japan, and India, has a rapidly expanding asparagine market due to its growing pharmaceutical, food, and beverage industries. China's large-scale manufacturing capabilities make it a significant supplier of Asparagine domestically and globally. The region is witnessing growth in nutrition and health supplement sectors, driving the need for amino acids such as Asparagine. The evolving regulatory landscape and increasing consumer health consciousness further shape the market dynamics. In EMEA, Europe leads with a mature market for Asparagine, particularly within the pharmaceutical and nutraceutical industries. The steadily aging population contributes to the region's significant demand for dietary supplements and parenteral nutrition, which includes Asparagine. The market needs to be developed in the Middle East and Africa but presents potential for growth with rising health awareness and changing dietary habits.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Asparagine Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Rising health consciousness and demand for dietary supplements
- Increased investment for R&D in pharmaceutical industry
- Ongoing innovations in the food and beverage industry

Market Restraints
- Fluctuations in prices of raw materials

Market Opportunities
- Development of novel pharmaceutical formulations containing asparagine.
- Rise in precision medicine and targeted therapies

Market Challenges
- Stringent regulations and standards regarding the use of asparagine

Market Segmentation Analysis
- Type:Growing demand for Anhydrous asparagine in dry-blending nutritional formulations
- Application: Rising usage of Asparagine for enhancing nutritional value and flavor profiles of products

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Asparagine Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Asparagine Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Jazz Pharmaceuticals plc has announced a significant development with the European Commission's approval of Enrylaze (JZP458), a recombinant Erwinia asparaginase, under the brand name Rylaze in the U.S. and Canada. This endorsement authorizes Enrylaze for use within multi-agent chemotherapy treatments for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) for those aged one month and older who are intolerant and have an inadequate response to E. coli-derived asparaginases. [Published On: 2023-09-21]

Kaimisi New Material and Bicells to build 2,000 t per year L-asparagine project and 100 t per year GABA project

Shandong Kaimisi New Material Technology Co., Ltd. has announced the successful publication of their Environmental Impact report, approved on October 11 by the Dongying Municipal Ecological Environment Bureau, for a pioneering L-asparagine production project using biofermentation. The project, situated in Dongying City's Economic Development Zone, sees an investment of approximately USD 28.17 million aimed at erecting a state-of-the-art facility capable of yielding 2,000 tons per annum (t/a) of this essential amino acid, known for its extensive applications across the food, medical, and environmental protection industries. [Published On: 2022-01-11]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Asparagine Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Asparagine Market, highlighting leading vendors and their innovative profiles. These include BioVendor Group, Creative Enzymes, Duchefa Biochemie B.V., Jazz Pharmaceuticals, Inc., LGC Limited, medac GmbH, Merck KGaA, MP Biomedicals, LLC, Porton Biopharma Limited, Taj Pharmaceuticals Ltd., Tokyo Chemical Industry (India) Pvt. Ltd., and VWR International, LLC.

Market Segmentation & Coverage

This research report categorizes the Asparagine Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Asparagine Anhydrous
- Asparagine Monohydrate

Application
- Food & Beverage
- Pharmaceutical

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-C1290E70D506

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising health consciousness and demand for dietary supplements
  - 5.1.1.2. Increased investment for R&D in pharmaceutical industry
  - 5.1.1.3. Ongoing innovations in the food and beverage industry
- 5.1.2. Restraints
  - 5.1.2.1. Fluctuations in prices of raw materials
- 5.1.3. Opportunities
  - 5.1.3.1. Development of novel pharmaceutical formulations containing asparagine.
  - 5.1.3.2. Rise in precision medicine and targeted therapies
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulations and standards regarding the use of asparagine
5.2. Market Segmentation Analysis
- 5.2.1. Type:Growing demand for Anhydrous asparagine in dry-blending nutritional formulations
- 5.2.2. Application: Rising usage of Asparagine for enhancing nutritional value and flavor profiles of products
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Asparagine Market, by Type

6.1. Introduction
6.2. Asparagine Anhydrous
6.3. Asparagine Monohydrate

7. Asparagine Market, by Application

7.1. Introduction
7.2. Food & Beverage
7.3. Pharmaceutical

8. Americas Asparagine Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Asparagine Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Asparagine Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
- 11.3.1. Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
- 11.3.2. Kaimisi New Material and Bicells to build 2,000 t per year L-asparagine project and 100 t per year GABA project
11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

12.1. Key Company Profiles
12.2. Key Product Portfolio